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Abstract: Conventional anti-cancer therapies based on chemo- and/or radiotherapy represent highly
effective means to kill cancer cells but lack tumor specificity and, therefore, result in a wide range of
iatrogenic effects. A promising approach to overcome this obstacle is spliceosome-mediated RNA
trans-splicing (SMaRT), which can be leveraged to target tumor cells while leaving normal cells
unharmed. Notably, a previously established RNA trans-splicing molecule (RTM44) showed efficacy
and specificity in exchanging the coding sequence of a cancer target gene (Ct-SLCO1B3) with the
suicide gene HSV1-thymidine kinase in a colorectal cancer model, thereby rendering tumor cells
sensitive to the prodrug ganciclovir (GCV). In the present work, we expand the application of this
approach, using the same RTM44 in aggressive skin cancer arising in the rare genetic skin disease
recessive dystrophic epidermolysis bullosa (RDEB). Stable expression of RTM44, but not a splicingdeficient control (NC), in RDEB-SCC cells resulted in expression of the expected fusion product at the
mRNA and protein level. Importantly, systemic GCV treatment of mice bearing RTM44-expressing
cancer cells resulted in a significant reduction in tumor volume and weight compared with controls.
Thus, our results demonstrate the applicability of RTM44-mediated targeting of the cancer gene
Ct-SLCO1B3 in a different malignancy.
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1. Introduction
Splicing is a naturally occurring process that takes place during the generation of
fully active messenger RNA (mRNA) and is mediated by the cell’s own spliceosome.
Herein, noncoding regions (introns) are excised from the pre-mRNA and the coding regions
(exons) are fused together to form the mature mRNA. The pre-dominant form in eukaryotic
cells is cis-splicing, where the exons from one pre-mRNA transcript are joined together
(Figure 1A). In contrast, RNA trans-splicing involves the joining of exons originating from
more than one pre-mRNA transcript. Trans-spliced RNA can encode new proteins or
non-coding regulatory transcripts, not only resulting in increased proteome complexity,
but also contributing to the regulation of gene expression [1].

Figure 1. Schematic representation of cis- versus trans- splicing reactions and SMaRT approach. (A) Different types of RNA-splicing. Cis-splicing occurs within one pre-mRNA transcript whereas trans-splicing
fuses exons from different pre-mRNA transcripts together. (B) SMaRT technology in suicide gene therapy
approach. An RNA trans-splicing molecule targets the intronic region of a cancer target gene thereby
inducing a trans-splicing reaction and generating a new chimeric RNA transcript consisting of exon1
of the target gene and a suicide gene provided by the RTM. Abbreviations: BD, binding domain; BP,
branch point; PPT, polypyrimidine tract; ss, splice site; RTM, RNA trans-splicing molecule.

Although less frequent in humans, RNA trans-splicing events have been observed
in several physiological and pathological conditions including cancer [2], highlighting a
potential role in human health and disease. In prostate cancer e.g., chimeric RNAs have
been detected at higher frequency in malignant samples compared to matched healthy
tissue [3]. Although detection of these new chimeric transcripts is challenging, they are
suggested to have great potential as biomarkers or even as new therapeutic targets [4].
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The process of fusing two different mRNA transcripts together by a single transsplicing reaction has also opened up new avenues for RNA reprogramming. In 1999,
Putaraju et al. described for the first time a spliceosome-mediated mRNA trans-splicing
approach (abbreviated “SMaRT”) capable of replacing the 30 region of the pre-mRNA for
the β-subunit of human chorionic gonadotropin gene 6 in a human lung cancer model
system [5]. Since then, this technology has been developed further in order to replace
50 - [6,7], 30 - [8–10], or even internal exons [11,12] of a target pre-mRNA. While SMaRT
technology has been primarily developed for gene therapeutic approaches to replace exons
carrying disease-causing mutations (as reviewed by [13]), it has also drawn significant
attention as an emerging tool for targeted anti-cancer therapy. The goal of targeted cancer
therapies is the elimination of tumor cells while leaving normal cells unharmed. In the case
of SMaRT, this has been achieved by trans-splicing a suicide gene to a cancer-specific target,
thereby enforcing its cell-restricted expression. This approach has successfully been used to
deliver the suicide gene thymidine kinase from herpes simplex virus 1 (HSVtk) into cancer
cells, rendering cells sensitive to treatment with the prodrug ganciclovir (GCV) [14–17].
In detail, the HSVtk enzyme catalyzes the phosphorylation of GCV into an active cytotoxin
that causes cell death by terminating DNA replication [18].
The trans-splicing reaction is facilitated by an artificially engineered pre-mRNA transsplicing molecule (RTM) (Figure 1B) consisting of a binding domain (BD) complementary
to intronic regions of a cancer-specific target molecule, splicing elements (BP, branch point;
PPT, polypyrimidine tract; 30 ss, splice site), and the coding sequence of the suicide gene
lacking its intrinsic translation start codon. Upon correct trans-splicing, a new chimeric
transcript is generated, merging the 50 region of the target mRNA and the suicide gene
together. As the translation of the chimeric protein is initiated from the start codon provided
by the target mRNA, the specificity of the approach is highly dependent on the cancerspecific expression of the target mRNA [19]. In this respect, cancer-type solute carrier
organic anion transporting polypeptide 1B3 (Ct-SLCO1B3) has been shown to be a highly
cancer-specific transcript in several different cancers [20–22]. Ct-SLCO1B3 is a variant
of the liver-type SLCO1B3 (Lt-SLCO1B3) that arises from transcription initiation at an
alternate exon 1 (Ct-exon1) located within the large intron 3 of Lt-SLCO1B3. Our previous
efforts concentrated on generating a potent RTM (RTM44) able to target Ct-SLCO1B3 and
introduce the suicide gene HSVtk into colorectal cancer cells, rendering them sensitive to
treatment with GCV [23].
In the present work, we evaluated the efficacy of this specifically designed RTM44
in a different cancer type, cutaneous squamous cell carcinomas (cSCCs), which arise in
patients with the rare genetic skin disease recessive dystrophic epidermolysis bullosa
(RDEB) [24,25]. RDEB is caused by mutations in the gene COL7A1, encoding type VII
collagen, the main component of anchoring fibrils that are essential for adhesion of the
epidermis to the dermis. As a consequence, patients suffer from blister formation on the skin
and mucous membranes, as well as additional comorbidities such as mitten deformities,
pseudosyndactyly, and failure to thrive. The overall incidence and prevalence of RDEB is
3.05 and 1.35 per one million live births, as estimated by the U.S. National EB registry [26].
Repetitive cycles of wounding, inflammation, and infection predispose patients to the
development of aggressive cSCC, which represents a life-threatening condition in this
patient cohort. Epidemiology data from the Australasian EB registry cohort reported a
cumulative risk of cSCC development of 76.1% by the age of 35 and a median time to death
after first cSCC of 4 years [27].
Importantly, our group has previously shown that Ct-SLCO1B3 constitutes a cancerspecific target gene in RDEB-SCC [23]. By using primers that discriminate between liverand cancer-type variants, we were able to demonstrate that Ct-SLCO1B3 transcripts were
significantly expressed in RDEB-SCC cell lines and patient tumor biopsies as compared with
non-tumor RDEB or normal human keratinocyte cell lines, making this variant transcript a
potential therapeutic target as well in this tumor entity. Using the same RTM44 as described
by Sun et al. [17], we demonstrate here the successful introduction of HSVtk into the coding
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sequence of Ct-SLCO1B3 in the presence of functional RTM44, and tumor cell killing in cell
culture and as well as in a xenograft mouse model for RDEB-SCC following treatment with
the prodrug GCV. This study highlights the translatability of a specially designed RTM
molecule to different malignancies.
2. Results
2.1. RTM44 Facilitates the Trans-Splicing Reaction in RDEB-SCC Cells
In the present study, we utilized RTM44, previously proven to target Ct-SLCO1B3
in a colorectal cancer model. The design and generation of RTM44 has been described
in detail by Sun et al. [17]. Briefly, RTM44 consists of a 225-bp BD complementary to
intronic sequences immediately following exon 1 of the Ct-SLCO1B3 transcript. RTM44
was further modified to remove any start codons within the BD, as well as cryptic splice
sites within a minimal functional HSVtk sequence. This eliminated potential expression of
functional HSVtk enzyme directly from the RTM, and reduced undesired splicing within
the HSVtk coding region, which could result in a non-functional enzyme. A 3× FLAG-tag
incorporated into the C-terminus of the HSVtk sequence facilitated the identification of
the chimeric trans-splicing product (Figure 2A). In addition to RTM44, we used a positive
control vector encoding the expected Ct-HSVtk fusion product (PC), and a negative control
vector encoding a splicing-deficient RTM44 (NC) (Figure 2A). All three vectors were
used for retroviral transduction of the cancer cell line RDEB-SCC2 established from an
RDEB patient [28].

Figure 2. Trans-splicing in RDEB-SCC cells. (A) RDEB-SCC2 cells were retrovirally transduced with
vectors encoding either RTM44, a positive control (PC) expressing the expected fusion transcript or a
splicing deficient RTM designated as negative control (NC). (B) Correct integration of the various vectors
into the host genomic DNA (gDNA) was confirmed by PCR (top panels) using vector- and BD-specific
forward primers (fp3681 and fp3648, respectively), as well as an HSVtk-specific reverse primer (rp819).
Additionally, we confirmed trans-splicing on the mRNA level by sqRT-PCR using primers specific for the
expected fusion product (fp3680 and rp819). GAPDH served as control (lower panels). (C) Sequencing
of the PCR-amplified trans-splicing product confirmed accurate trans-splicing between the target premRNA and RMT44, resulting in a fusion transcript consisting of Ct-exon1 and HSVtk. (D) Detection of
trans-splicing product on the protein level using an antibody against the FLAG-tag fused to the HSVtk
sequence on the C-terminus. Alpha-actinin was used as a loading control. The triangles indicate the
fusion protein of Ct-SLCO1B3 and HSVtk (predicted MW of 42 kDa).
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We confirmed the integration of the full-length RTM cassette and its variants into
the genome of the RDEB-SCC cells by PCR amplification using vector- and BD-specific
forward primers (fp3681 and fp3648, respectively) and an HSVtk-specific reverse primer
(rp819) (Figure 2B). Using primers specific for the expected fusion product (fp3680/rp819),
we performed sqRT-PCR to detect the trans-splicing product in total RNA isolated from
each cell line. We detected a PCR product of the expected size (206 bp) only in RDEB-SCC
lines transduced with the RTM44- and PC- vectors, but not in the parental line or those
transduced with the splicing-deficient NC-vector (Figure 2B). Sequencing of the amplified
products showed the correct sequence at the expected junction between Ct-exon1 and
HSVtk (Figure 2C), thus confirming that accurate trans-splicing had occurred.
Expression of the expected fusion protein was confirmed by Western blot analyses of
total cell lysates using an anti-FLAG antibody in RDEB-SCC2 (Figure 2D) and in a second
RDEB-SCC cell line (Figure S1A). We detected robust expression of an approximately 42
kDa protein, representing the expected fusion product, in cells transduced with the PC
vector. Importantly, we detected a similar protein band in RDEB-SCC cells stably expressing
RTM44 that was absent in parental cells or those transduced with the NC vector, signifying
that this protein was expressed from the trans-spliced product.
We also detected FLAG-tagged proteins of lower molecular weight (MW) in our
Western blot analyses, which we further investigated in order to determine their origin
(Figure S2). We identified several internal start codons within the encoded HSVtk sequence
that could potentially lead to translation of truncated versions of the enzyme directly
from the RTM in the absence of trans-splicing. Specifically, translation initiation from the
first three internal ATGs would result in proteins with predicted MWs of 37.3, 34.5, and
30.7 kDa, respectively, which correspond closely to the observed MWs of the truncated
variants detected by Western blot analysis. In order to verify the origin of each HSVtk
version, we mutated each of these three start codons in the RTM44 vector separately (MTK1,
MTK2, and MTK3), and transfected each into HEK293 cells. These cells lack the expression
of Ct-SLCOB3, thereby enabling the evaluation of HSVtk expression and activity in the
absence of trans-splicing. Western blot analysis of cell lysates confirmed that the 37.3 and
34.5 kDa protein bands were derived from translation initiation at internal ATGs. However,
the identity of the proteins with apparent MW of ~30 and ~40 kDa remained undetermined
by this analysis. Nevertheless, based on the existing literature, all of these truncated HSVtk
variants are expected to lack an intact ATP-binding site required for activity, and thus
represent inactive enzymes [29]. Indeed, despite the expression of these truncated HSVtkrelated variants in HEK293 cells, the viability of these cells in GCV-killing assays confirmed
the lack of activity of any of these proteins.
Taken together, the data confirmed that successful generation of a new chimeric mRNA
and active HSVtk-fusion enzyme only occurred when both the functional RTM44 and its
Ct-SLCO1B3 pre-mRNA target were present in cells.
2.2. RTM44 Renders RDEB-SCC Sensitive to Ganciclovir Treatment In Vitro
To demonstrate that RTM44 is capable of rendering tumor cells susceptible to treatment
with GCV, parental RDEB-SCC cells and cells stably expressing RTM44, PC, or NC, were
treated with increasing concentrations of GCV (10–200 µM) for up to 72 h. Cell confluence
and cell viability were then assessed by cell imaging and MTT assay, respectively (Figure 3). We observed a dose-dependent reduction in confluence of cells harboring RTM44
and PC upon GCV treatment (Figure 3A,B). A concentration of 10 µM already showed
significant decrease in cell confluence compared with parental and NC-expressing cells.
Notably, increasing concentrations of GCV (>50 µM) induced a general cytotoxicity in cells,
as demonstrated by significant reduction of cell confluence in NC and parental cells.
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Figure 3. Impact of trans-splicing cancer gene therapy on cell viability and confluence in vitro. RDEBSCC2 cells were stably transduced with the various RTM44 vectors and treated with increasing
concentrations of GCV (0—200 µM) for 72 h. (A,B) Cells were seeded in 96-well plates and cell
confluence was measured using life cell imaging (Tecan Spark Cyto). Each experiment was carried
out in quadruplicates and the mean ± SD of three experiments are shown. (C,D) Cell viability was
assessed by MTT assay. RTM44 rendered cells sensitive to the treatment of GCV at all concentrations
tested compared with the splicing-deficient negative control (NC) or parental cells. Each experiment
was carried out in quadruplicates and mean ± SD of four experiments are shown. Statistical analysis:
Mann–Whitney test *** p < 0.0001.

These data were corroborated by cell viability measurements, which were significantly
decreased in cells harboring RTM44 and PC upon GCV treatment of concentration ≤10 µM
when compared with untreated controls (Figure 3C). GCV treatment with 10 µM of RDEBSCC2 cells transduced with PC and RTM44 constructs displayed a viability of 19.72% and
37.89%, respectively, after 72 h of treatment. In contrast, parental RDEB-SCC2 were largely
unaffected (viability of 80.85%), and NC-transduced cells exhibited a viability of 90.02%.
At higher concentrations of GCV, reduced metabolic activity in the parental and NC cells
was also observed compared with the untreated controls. Similar effects were observed in
a second RDEB-SCC cell line (Figure S1B).
2.3. RTM44 Shows Efficacy in a Xenograft Mouse Model for RDEB-SCC
To evaluate the feasibility and efficacy of our SMaRT-cancer suicide gene strategy
in vivo, RDEB-SCC2 cells stably expressing either RTM44 or the splicing-incompetent NC
were injected intradermally into SCID-beige mice. Mice were monitored regularly for
tumor development and treated with either GCV (100 mg/kg/day i.p. for 14 days) or
PBS when the average tumor volume was ~50 mm3 . NC-tumors grew at a decreased
rate compared with RTM44-tumors (Figure 4A, left and right panel). NC-tumors grew
steadily and with similar kinetics in mice that were treated with PBS or GCV (Figure 4A,
left panel), indicating that GCV had no effect on NC-tumors. However, the growth of
RTM44-tumors was significantly inhibited in mice receiving systemic GCV treatment as
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compared with those that received PBS (Figure 4A, right). At the end of the treatment,
RTM44-tumors excised from mice that had received GCV treatment were visibly smaller
(Figure 4B) and weighed significantly less (Figure 4C) than RTM44-tumors that had been
exposed to PBS. In contrast, the weight and size of NC-tumors were similar regardless
of treatment (Figure 4D). Furthermore, TUNEL staining in whole tumor tissue sections
identified areas of increased apoptosis in RTM44- compared with NC-tumors that had
been exposed to GCV, indicating that ongoing apoptosis contributed to the tumor growth
inhibition observed in these mice (Figure S3). Thus, our results indicate that RDEB-SCC2
cells expressing RTM44 are susceptible to GCV treatment applied systemically, leading to
control of tumor outgrowth in a xenograft animal model.

Figure 4. Tumors expressing RTM44 are sensitive to GCV treatment in vivo. (A) Growth kinetics of
NC- and RTM44-tumors in PBS- and GCV-treated mice (100 mg/kg/day) over a period of 14 days.
GCV treatment had no impact on outgrowth of NC-tumors, but significantly inhibited growth of
RTM44-tumors. Number of tumors per treatment group: NC-PBS, n = 5; NC-GCV, n = 7; RTM44-PBS,
n = 4; RTM44-GCV, n = 10; statistical analysis: non-parametric t-test, adjusted p-values corrected for
multiple comparisons using the Bonferoni–Dunn method. (B) Tumor volume was calculated before
(day 0) and at the end (day14) of treatment using the formula V = 12 (L × W2 ). Statistical significance
was determined using the Mann–Whitney test, *** p < 0.001; ** p = 0.01. (C,D) RTM-tumors exposed
to GCV treatment were visibly smaller and weighed significantly less at the end of the treatment
compared with tumors of the PBS-treated control group. Mann–Whitney test, ** p < 0.01.

3. Discussion
In the present study, we show that an RNA trans-splicing molecule (RTM44) is able to
reprogram the cancer target gene Ct-SLCO1B3 in order to express thymidine kinase from
herpes simplex virus (HSVtk), rendering cancer cells sensitive to treatment with the prodrug
ganciclovir in both in vitro and in vivo experiments. This effect is ascribed to a successful
trans-splicing reaction, followed by expression of an active chimeric HSVtk, and consequent
induction of apoptosis, all of which could not be observed in tumor cells containing the
trans-splicing deficient variant of the RTM (NC). Notably, the efficacy of RTM44 has also
previously been demonstrated in a colorectal cancer model [17], thereby highlighting its
translatability to other malignancies that express Ct-SLCO1B3. RDEB is a rare genetic skin
disease caused by loss of function mutations in the gene COL7A1, leading to tissue fragility
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in skin and mucous membranes. Patients suffer from excessive scarring and chronic open
wounds that often become infected and are at high risk of turning malignant [30]. cSCC
arises in nearly all RDEB patients and constitutes a life-threatening complication [25].
Notably, these SCCs predominantly develop at sites of chronic wounding, which makes a
clear and early diagnosis very challenging. Therefore, new therapeutic approaches that
can be applied even at premalignant stages, or in tissue wherein only a few malignant
cells are present and could be targeted, is highly warranted in this patient group. SMaRT
technology may also be suitable in this context, as it should act only in cells that express the
cancer-specific target gene. We designed RTM44 to trans-splice to the tumor-specific target
pre-mRNA of Ct-SLCO1B3. We have previously shown that Ct-SLCO1B3 is expressed
in RDEB-SCC cells [23], (Figure S4A). However, for this technology to be applicable at
the pre-malignant stage, its expression in chronically inflamed tissue and wounds in this
patient cohort still needs to be investigated.
Furthermore, we were able to detect Ct-SLCO1B3 mRNA levels in late stages of head
and neck SCC tissue arising in the normal population (Figure S4B), suggesting that this
could be an additional cancer that could be targeted by RTM44. One aspect that needs to
be considered is the level of target gene expression in the cancer cells, as this was shown
to influence the efficacy of the trans-splicing approach. As shown by Sun et al. 2018,
colorectal cancer cells with lower levels of Ct-SLCO1B3 RNA expression exhibited reduced
susceptibility to this approach compared with cancer cells expressing high levels of the
target gene. Therefore, it can be hypothesized that a certain threshold of the target gene
needs to be expressed in order to generate sufficient levels of the trans-splicing product.
Accordingly, the level of Ct-SLCO1B3 expression should be determined for each tumor
entity and patient, and these data should be used to select those patients most likely to
benefit from this treatment strategy.
In order to advance this strategy further, several aspects of the SMaRT technology still
need to be comprehensively investigated. One issue is the potential for off-target events
due to unspecific trans-splicing. When using RNA trans-splicing approaches for gene
correction in monogenetic diseases [7,8,31–36], it might be possible to overlook off-target
events as the introduced gene is not expected to be toxic. However, in the context of suicide
gene therapy, any off-target reactions could also induce cell death in normal healthy cells,
underscoring the need for comprehensive analysis of such events before moving forward
to clinical evaluation. This becomes particularly important when using very potent suicide
genes such as diphtheria toxin, where single molecules can kill the target cells [37]. In this
case, even a very low frequency of unspecific trans-splicing events would cause severe
side effects. In contrast to bacterial toxins, whose expression can directly kill cells, the
HSVtk/GCV system induces cell death indirectly via DNA replication termination and the
activation of DNA damage response [38]. This requires a certain level of GCV-mediated
damage signal to induce apoptosis in the cells. Therefore, it has been suggested that low to
moderate levels of off-target events may be insufficient to elicit cell death [16]. In line with
this, transient transfection of RTM44 into HEK293 cells lacking expression of the target gene
Ct-SLCO1B3 did not induce GCV-mediated cell killing (Figure S1), indicating that off-target
events are rare or kept under a certain threshold, at least under the conditions investigated.
Additionally, sequence optimization of both vector backbone and RTM is important in
order to exclude cis-splicing events, or direct expression of the suicide gene from the vector.
We have addressed this issue by mutating potential cis-splice sites and start codons in the
BD that would result in a direct translation from the RTM. Within the HSVtk sequence,
several active ATG sites resulted in truncated versions of the suicide gene, which we could
confirm to be inactive owing to the lack of the ATP binding site (Figure S2). However,
competitive or dominant negative effects of these truncated forms cannot be excluded,
especially when the trans-splicing reaction is less efficient. Therefore, additional sequence
optimization needs to be addressed, and any potential start codon within the HSVtk
sequence should be modified in future studies.
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The BD represents another crucial element of the RTM that can be optimised, as it
provides specificity by binding to the desired target gene. Off-target events can potentially
arise through sequence homology with other, unrelated pre-mRNAs. Notably, for RTM44,
no homology between the BD and human genomic sequences other than the target gene
SLCO1B3 itself could be detected with NCBI-Blast. However, unspecific trans-splicing
events cannot be excluded and comprehensive analyses of off-target events induced by the
RTM using next-generating sequencing platforms (such as RNAseq) are highly warranted
in order to accurately assess both the specificity and efficiency of the approach.
Finally, the issue of in vivo delivery warrants attention, as this constitutes the bottleneck of any successful gene therapeutic approach. In the present work, we used retroviral
vectors to stably introduce the RTM into tumor cells. However, for an in vivo application,
the use of retrovirus- or lentivirus-mediated gene delivery systems always harbors the risk
of tumor induction in patients owing to possible random integration into the genome [39]
or the induction of inflammatory responses [40], and would thus not be the preferable
delivery platform for patients. As such, it will be necessary to investigate other gene
delivery options with better in vivo applicability. In the context of RDEB-SCC, these tumors
are more accessible than other tumor types, which offers the opportunity for local delivery
of the RTM. In vivo cell transfection could be enhanced by cloning the RTM cassette into
minicircles [41], which, because of their small size and lack of bacterial backbone sequences,
show improved transfection efficiencies and in vivo applicability. Furthermore, complexing
vectors to highly branched poly (ß-amino ester)s (HPAEs) have already been shown to
efficiently deliver genes into skin by injection or even topical application in an RDEB mouse
model [42]. Moreover, these can be combined with more mechanical means of gene delivery
via microneedle injections [43], gene gun delivery [44], or sonoporation [45].
Taken together, SMaRT technology used in a cancer suicide gene therapy approach
represents a promising therapeutic strategy. Further studies should focus on optimizing
the technology including trans-splicing efficiency, specificity, and delivery.
4. Materials and Methods
4.1. Cell Cultures
RDEB-SCC2 were established from a SCC tumor arising in an RDEB patient (COL7A1:
c.6269delC/p.P2090fsX116; c.8253_8254delAG/p.R2751SfsX38; [28]). The cells were routinely grown in Green’s medium (DMEM and Ham F-12 (both from Hyclone, Perbio
Science, Bezons, France) 2:1) supplemented with 10% FCS II (Biochrom, Berlin, Germany),
2% L-glutamine (Thermo Fisher Scientific, Waltham, MA, USA), and 1% sodium-pyruvate,
0.1416 mM adenine, 5 µg/mL insulin, 0.4 µg/mL hydrocortisone, 47 ng/mL cholera
toxin, 0.00137 ng/mL triiodothyronine, and 10 ng/mL EGF (all from Sigma-Aldrich, St.
Louis, MO, USA ), at 37 ◦ C and 5% CO2 . Human embryonic kidney cells (HEK293AD)
were purchased from Stratagene (La Jolla, CA, USA) and cultured in DMEM + 10% FC +
penicillin/streptomycin.
4.2. RTM44
The design and generation of RTM44, NC, and PC was described in detail by Sun
et al. [17] and subcloned into the retroviral vector pDON (pDON-AI-2, Takara –Bio,
Kusatsu, Shiga, Japan). All resulting vectors (pDON-RTM44 = RTM44, pDON-NC = NC,
pDON-PC = PC) were transduced into RDEB-SCC2 cells and further FACS-sorted based
on their GFP expression to >90% purity.
4.3. Transient Transfection
HEK293AD cells were cultured in T25 cm2 until reaching a confluence of 80% and
transfected with Xfect reagent (Clontech, Mountain View, CA, USA), according to the
manufacturer’s protocol. Forty-eight hours after transfection, cells were detached and
re-seeded in replicate wells of a 96-well plate, and treated with 100 µM GCV the next day.
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Cell viability was assessed by MTT assay after 72 h of incubation. For transient transfection,
trans-splicing constructs encoded in bacterial plasmids (pCDNa3.1) were used.
4.4. PCR Analysis
For detection of endogenous trans-splicing between SLCO1B3 and the RTM RNA, we
performed a one-step RT PCR according to the protocol for Luna® Cell Ready One-Step RTqPCR Kit Protocol (New England Biolabs, Frankfurt, Germany). Briefly, 100,000 cells were
washed with PBS and then lysed with the cell lysis mix, according to the manufacturer’s instructions, and stored at −80 ◦ C. RT-qPCR was performed according to the Luna Universal
One-Step RT-qPCR Kit protocol. For each reaction, 4000 cells were used. The following forward primer binding CT-SLCO1B3 exon 1 (fp3680: 50 -TTGGCTTGGGCTCAGAGA-30 ) and
reverse primer complementary to HSVtk (rp819: 50 -AGATGTTCGCGATTGTCTCGGAA30 ) were used. PCR detecting GAPDH (fp: 50 - GCC AAC GTG TCA GTG GTG GA-30 ;
rp: 50 CAC CAC CCT GTT GCT GTA GCC-30 ) served as internal control. PCR conditions:
reverse transcription at 55 ◦ C for 10 min followed by an initial denaturation step at 95 ◦ C
for 1 min; 40 cycles of denaturation at 95 ◦ C for 10 and extension at 60 ◦ C for 30 s.
Correct integration of the vectors encoding RTM, NC, or PC within the genome of
RDEB-SCC was verified by standard PCR analysis using forward primers complementary to
the binding domain (BD) (fp3648: 50 -CCTGCTAAAAATCAGCATTCCTAA-30 ) or the vector
sequence upstream of the BD (fp3681: 50 -GCTTCCTTTGTCCCCAATCT-30 ) in combination
with the reverse primer binding HSVtk (rp819).
4.5. Western Blot Analysis
Whole cell lysates were prepared from each RDEB-SCC cell line using RIPA buffer
(Santa Cruz Biotechnology, Dallas, TX, USA) supplemented with 0.1% protease inhibitor
cocktail (Roche, Basel, Switzerland). Samples were mixed with 4× NuPUGE LDS sample
buffer (Invitrogen, Carlsbad, CA, USA) with 3% β-Mercaptoethanol and separated on a
NuPAGE 4–12% Bis-Tris gel (Invitrogen) under denaturing conditions. Afterwards, the
proteins were electroblotted onto a PVDF membrane (GE Healthcare, Buckinghamshire,
UK) and blocked with 5% skim milk in TBS/0.1% Tween 20 for 1 h at RT. The membrane was
incubated with monoclonal mouse-anti-Flag-tag antibody (Wako 1:1000) in blocking buffer
over night at 4 ◦ C followed by incubation with the secondary HRP-labeled anti-mouse
IgG antibody (DAKO 1:200) for 1 h at RT. Alpha actinin staining served as loading control
using a polyclonal rabbit-anti-alpha-actinin (Santa Cruz Biotechnology, 1:1000) antibody
followed by incubation with HRP-labeled anti-rabbit IgG antibody (DAKO, Vienna, Austria;
1:200). Protein bands were visualized using Immobilon Western Chemiluminescence HRP
Substrate (Merck Millipore, Darmstadt, Germany) and ChemiDoc XRS system (Bio-Rad,
Munich, Germany).
4.6. TUNEL Staining
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay was
performed to highlight apoptotic cells in tumor sections using the In Situ Cell Death Detection Kit TMR red (Roche, Basel, Switzerland), according to the manufacture’s protocol.
Briefly, tissue sections were fixed with 4% paraformaldehyde for 20 min at RT and permeabilized with PBS containing 0.1% Triton X-100 and 0.1% BSA. Afterwards, tissue sections were
stained with 50 µL TUNEL reaction mixture for 1 h at RT. Cell nuclei were staining using
4’, 6-diamidino-2-phenylindole (DAPI). Immunofluorescence on whole tissue sections was
assessed with the Olympus VS120-LD100 slide loader system (Olympus, Tokyo, Japan).
4.7. MTT Assay and Confluency Measurement
Cells were seeded into a 96-well plate at a density of 5000 cells/well in 100 µL medium
and incubated at 37 ◦ C for 24 h. The next day, 100 µL medium supplemented with
ganciclovir (10–200 µM) was added. Cells grown in medium only served as negative control.
After 72 h of incubation, 25 µL of MTT stock solution (5 g/L Thiazolyl Blue Tetrazolium
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Bromide in PBS, Abcam, Cambridge, UK) was added and the plate was incubated for 1 h at
37 ◦ C. Afterwards, the supernatant was aspirated and cells were lysed by adding 100 µL
DMSO/glycine solution (6 Vol DMSO + 1 Vol 0.1 M glycine/NaOH pH 10.2). The plate
was incubated for 10 min at RT on a plate shaker at 500 rpm. Finally, absorbance (reduction
of MTT to formazan) was measured at 492 nm/670 nm using the TECAN Spark M10 plate
reader (TECAN, Grödig, Austria). For confluence measurement, cells were seeded into a
96-well plate at a density of 2000 cells/well and treated as described above. After 72 h of
treatment, cell confluence within the wells was measured and brightfield pictures were
acquired using TECAN Cyto M10 plate reader (TECAN, Grödig, Austria).
4.8. Animal Model
Immunodeficient SCID beige mice (CB17.Cg-Prkdcscid Lystbg-J /Crl) were purchased
from Charles River (Sulzfeld, Germany) and maintained in the SPF animal facility of the
Paracelsus Medical University Salzburg, Austria. All animal experiments were conducted
in accordance with the guidelines of the facility and with approval of the local regulatory
committee (license number: TVA 20901-TVG/72/7-2014).
RDEB-SCC2 (3.5 × 106 cells) carrying either RTM44 or NC were injected intradermally
into the shaved abdomen of the mice. After the tumors reached a volume of 50 mm3 ,
ganciclovir (100 mg/kg) was administered intra peritoneally (i.p.) every day. Tumor
volume was measured every second day with a digital caliper and tumor volume was
calculated using the formula V = 12 × length(L) × width(W)2 . After two weeks of treatment,
mice were sacrificed and tumors were excised for further analysis.
4.9. Statistical Analysis
GraphPad Prism software v. 9 (GraphPad, San Diego, CA, USA) was used for statistical
analysis. The data were analyzed for normal distribution using the Kolmogorov–Smirnov
test, D’Agostino and Pearson omnibus normality test, and Shapiro–Wilk normality test.
Unpaired t-test (two-tailed) was used when data in two groups were normally distributed.
When the data to be compared were not normally distributed, the Mann–Whitney test (twotailed) was performed. The results were considered significant at * p ≤ 0.05, ** p ≤ 0.01,
and *** p ≤ 0.001.
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